Hot Biotech Gainers: Illumina Inc. (NASDAQ:ILMN), NewLink Genetics Corporation (NASDAQ:NLNK), Oncothyreon Inc (NASDAQ:ONTY), Agios Pharmaceuticals(NASDAQ:AGIO), Sage Therapeutics(NASDAQ:SAGE)


Illumina, Inc. (NASDAQ:ILMN) announced its financial results for Q3 2014 on Monday and beat analyst expectations. The company reported revenue of $481 million, above the average estimates of $451.2 million and a 35 percent increase compared to $357 million in the third quarter of 2013. GAAP net income for the quarter was $93 million, or $0.63 per diluted share, above the average estimate of $0.56 and above the $31 million net income, or $0.22 per diluted share, for the third quarter of 2013. Illumina Inc. (NASDAQ:ILMN) in last trading activity advanced 9.17% to close at $179.55. Company weekly performance is 20.41% while its quarterly performance stands at -0.60%. Illumina Inc. (NASDAQ:ILMN) is -2.95% away from its 52 week high.

NewLink Genetics Corporation (NASDAQ:NLNK) on Oct. 20 announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group (RO.SW) (ROG.VX) (RHHBY), for the development of NLG919, NewLink’s IDO pathway inhibitor. The parties also entered into a research collaboration for the discovery of next generation IDO/TDO compounds. Under the terms of the agreement, NewLink will receive an upfront payment of $150 million. NewLink will be eligible to receive in excess of $1 billion in milestone payments based on achievement of certain predetermined milestones as well as escalating double-digit royalties on potential commercial sales of multiple products by Genentech. On last trading day NewLink Genetics Corporation (NASDAQ:NLNK) advanced 9.73% to close at $34.50. Its volatility for the week is 21.43% while volatility for the month is 13.33%. NLNK’s sales growth for past 5 years was 12.90% and its EPS growth for past 5 years was -23.40%. NewLink Genetics Corporation (NASDAQ:NLNK) monthly performance is 40.47%.

Wedbush began coverage on shares of Oncothyreon Inc. (NASDAQ:ONTY) in a report issued on Tuesday. The firm issued a buy rating and a $4.00 target price on the stock. On last trading day Oncothyreon Inc (NASDAQ:ONTY) advanced 9.83% to close at $1.90. Its volatility for the week is 7.88% while volatility for the month is 7.63%. ONTY’s EPS growth for past 5 years was -29.40%. Oncothyreon Inc (NASDAQ:ONTY) monthly performance is -7.77%.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) said it has initiated a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma that carry an isocitrate dehydrogenase-2 or IDH2 mutation. The study would enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has 15.30% insider ownership while its institutional ownership stands at 83.50%. In last trading activity company’s stock closed at $72.90.

On 24 September SAGE Therapeutics Inc (NASDAQ:SAGE) has elected Michael F. Cola to its Board of Directors. The company expects to benefit from the leadership expertise and insight of Cola. On Tuesday shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) closed at $38.12.


Leave a Reply

Your email address will not be published. Required fields are marked *